文献速递糖尿病

糖尿病预防计划结局研究中二甲双胍、生活方式干预与认知功能的关系

Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study.
PubMed 文献 · Diabetes Care · 2017-05-12

本研究在糖尿病预防计划结局研究(DPPOS)中评估生活方式干预、二甲双胍或安慰剂与认知功能的关联,并分析二甲双胍使用、新发2型糖尿病及血糖水平作为暴露因素。共2280名参与者(生活方式干预749名、二甲双胍776名、安慰剂755名)在DPPOS第8年和第10年接受认知评估。结果显示各干预组间认知无差异,2型糖尿病与认知无关,但第8年糖化血红蛋白较高与认知较差相关,累积二甲双胍暴露与认知无关。

要点

  • 生活方式干预、二甲双胍或安慰剂各组间认知功能无差异。
  • 第8年糖化血红蛋白较高与认知表现较差相关。
  • 累积二甲双胍暴露与认知无关,二甲双胍在DPPOS参与者中似乎对认知安全。

核心结论

  • 在DPPOS参与者中,强化生活方式干预或二甲双胍暴露与认知无关;较高的血糖水平与较差的认知表现相关;二甲双胍在DPPOS参与者中似乎对认知安全。

研究设计与样本

  • 糖尿病预防计划(DPP)持续2.8年,随后经过13个月的过渡期进入DPPOS;在DPPOS第8年和第10年(随机化后12年和14年)使用西班牙英语词语学习测验(SEVLT)、字母流畅性和动物流畅性测验、数字符号替换测验(DSST)及复合认知评分评估认知。
  • 共2280名参与者(生活方式干预749名、二甲双胍776名、安慰剂755名)接受了认知评估,年龄63.1±10.7岁;67.7%为女性,54.6%为非西班牙裔白人,20.7%为非西班牙裔黑人,14.6%为西班牙裔,5.5%为美洲印第安人,4.6%为亚裔;26.6%为APOE-ε4纯合子或杂合子。

主要发现

  • 认知评估时,安慰剂组2型糖尿病患病率(57.9%;P<0.001)高于生活方式干预组(47.0%)和二甲双胍组(50.4%)。
  • 二甲双胍组二甲双胍暴露时间(8.72年;P<0.001)高于安慰剂组(1.43年)和生活方式干预组(0.96年)。
  • 各干预组间认知无差异;2型糖尿病与认知无关;但经混杂因素调整后,第8年较高的糖化血红蛋白与较差的认知相关;累积二甲双胍暴露与认知无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined the association of the Diabetes Prevention Program (DPP) intervention arms (lifestyle intervention, metformin, and placebo) with cognition in the Diabetes Prevention Program Outcomes Study (DPPOS). We also examined metformin use, incident type 2 diabetes, and glycemia as exposures. RESEARCH DESIGN AND METHODS: The DPP lasted 2.8 years, followed by a 13-month bridge to DPPOS. Cognition was assessed in DPPOS years 8 and 10 (12 and 14 years after randomization) with the Spanish English Verbal Learning Test (SEVLT), letter fluency and animal fluency tests, Digit Symbol Substitution Test (DSST), and a composite cognitive score. RESULTS: A total of 2,280 participants (749 lifestyle, 776 metformin, and 755 placebo) aged 63.1 ± 10.7 years underwent cognitive assessments; 67.7% women, 54.6% non-Hispanic white, 20.7% non-Hispanic black, 14.6% Hispanic, 5.5% American Indian, and 4.6% Asian; 26.6% were homozygous or heterozygous for APOE-ε4. At the time of cognitive assessment, type 2 diabetes was higher in the placebo group (57.9%; P < 0.001) compared with lifestyle (47.0%) and metformin (50.4%). Metformin exposure was higher in the metformin group (8.72 years; P < 0.001) compared with placebo (1.43 years) and lifestyle (0.96 years). There were no differences in cognition across intervention arms. Type 2 diabetes was not related to cognition, but higher glycated hemoglobin at year 8 was related to worse cognition after confounder adjustment. Cumulative metformin exposure was not related to cognition. CONCLUSIONS: Exposure to intensive lifestyle intervention or metformin was not related to cognition among DPPOS participants. Higher glycemia was related to worse cognitive performance. Metformin seemed cognitively safe among DPPOS participants.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Luchsinger JA, Ma Y, Christophi CA, et al. Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2017. PMID: 28500216. doi:10.2337/dc16-2376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。